Featured Publications
Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype
Tyagi T, Ahmad S, Gupta N, Sahu A, Ahmad Y, Nair V, Chatterjee T, Bajaj N, Sengupta S, Ganju L, Singh SB, Ashraf MZ. Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. Blood 2013, 123: 1250-1260. PMID: 24297866, DOI: 10.1182/blood-2013-05-501924.Peer-Reviewed Original ResearchConceptsCalpain activityPlatelet reactivityProthrombotic phenotypeThrombus formationSoluble P-selectin levelsIncidence of thrombosisP-selectin levelsProthrombotic rolePlatelet hyperreactivitySolid tumorsVivo modelSmall subunit 1ThrombosisPathological conditionsAltered expressionHypoxic conditionsHypoxic environmentPlatelet proteinsHypoxiaExtreme altitudePresent studyCalpain functionPlateletsSubunit 1Phenotype
2019
Venous thrombosis at altitude presents with distinct biochemical profiles: a comparative study from the Himalayas to the plains
Prabhakar A, Chatterjee T, Bajaj N, Tyagi T, Sahu A, Gupta N, Kumari B, Nair V, Kumar B, Ashraf MZ. Venous thrombosis at altitude presents with distinct biochemical profiles: a comparative study from the Himalayas to the plains. Blood Advances 2019, 3: 3713-3723. PMID: 31765479, PMCID: PMC6880906, DOI: 10.1182/bloodadvances.2018024554.Peer-Reviewed Original ResearchConceptsVenous thromboembolismAdhesion molecule-1VTE patientsHA exposureMolecule-1Vascular cell adhesion molecule-1Toll-like receptor 2Intracellular adhesion molecule-1Receiver operator characteristic curve analysisCell adhesion molecule-1Operator characteristic curve analysisMost VTEElevated platelet countVascular endothelial growth factorCharacteristic curve analysisYounger age groupsPlatelet factor 4Endothelial growth factorDistinct biochemical profilesVon Willebrand factorAltered coagulationVTE eventsVenous thrombosisEndothelial activationPlatelet countCELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabó A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Tóth M, Belfort-DeAguiar R, Kibbey RG, Mani A. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nature Genetics 2019, 51: 1233-1243. PMID: 31358993, PMCID: PMC6675645, DOI: 10.1038/s41588-019-0470-3.Peer-Reviewed Original ResearchConceptsEarly-onset atherosclerosisMetabolic syndromeMetabolic syndrome traitsWhole-exome sequence analysisAttractive therapeutic targetPlatelet hyperactivationInsulin levelsPlasma insulinPlasma levelsInsulin sensitivityInsulin secretionTherapeutic targetPlatelet activationDisease mechanismsSyndrome traitsAtherosclerosisFunction mutationsSyndromeNovel lossInsulinMutationsSecretionAge associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
Jain K, Tyagi T, Patell K, Xie Y, Kadado AJ, Lee SH, Yarovinsky T, Du J, Hwang J, Martin KA, Testani J, Ionescu CN, Hwa J. Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. EBioMedicine 2019, 44: 28-40. PMID: 31130473, PMCID: PMC6604369, DOI: 10.1016/j.ebiom.2019.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAge FactorsAgedAged, 80 and overAgingAnimalsAntioxidantsApoptosisBiomarkersBlood PlateletsCardiovascular DiseasesComorbidityDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMiddle AgedOxidation-ReductionOxidative StressPlatelet ActivationPlatelet AdhesivenessReactive Oxygen SpeciesRisk AssessmentRisk FactorsConceptsRisk patientsMouse studiesPlatelet phenotypeMajor adverse cardiovascular eventsHigh cardiovascular risk patientsAdaptive increaseAdverse cardiovascular eventsCentral pathophysiological roleCVD risk patientsCardiovascular risk patientsAggressive antiplatelet therapyEffect of comorbidityAge group 40Young healthy subjectsAntiplatelet therapyCardiovascular eventsYear age cohortAdvanced ageCVD patientsGroup 40Healthy subjectsPathophysiological roleElderly populationCardiovascular pathologyPatients
2018
Genome-Wide Expression Analysis Suggests Hypoxia-Triggered Hyper-Coagulation Leading to Venous Thrombosis at High Altitude
Jha PK, Sahu A, Prabhakar A, Tyagi T, Chatterjee T, Arvind P, Nair J, Gupta N, Kumari B, Nair V, Bajaj N, Shanker J, Sharma M, Kumar B, Ashraf MZ. Genome-Wide Expression Analysis Suggests Hypoxia-Triggered Hyper-Coagulation Leading to Venous Thrombosis at High Altitude. Thrombosis And Haemostasis 2018, 118: 1279-1295. PMID: 29864786, DOI: 10.1055/s-0038-1657770.Peer-Reviewed Original ResearchMeSH KeywordsAdultAltitudeBlood CoagulationBlood Coagulation DisordersCase-Control StudiesGene Expression ProfilingGene Regulatory NetworksGene-Environment InteractionGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansHypoxiaMalePhenotypeRisk AssessmentRisk FactorsTranscriptomeVenous ThrombosisConceptsDeep vein thrombosisGenome-wide expression analysisDifferential expressionVenous thromboembolismEnrichment of genesGenes/pathwaysGene expression profilesHypoxia-responsive genesGene expression profilingRisk factorsGene OntologyOnset of VTEBioinformatics analysisExpression analysisExpression profilingExpression profilesPathway analysisMolecular mechanismsAdditional risk factorsQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionPathophysiology of DVTCommon cardiovascular diseaseRelevant pathwaysGenes
2017
Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia
Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 4763-4768. PMID: 28420787, PMCID: PMC5422823, DOI: 10.1073/pnas.1620458114.Peer-Reviewed Original ResearchConceptsExpression of NLRP3Venous thrombosisVenous thromboembolismIL-1βCaspase-1Activation of NLRP3Acute thrombotic eventsHypoxic conditionsIL-1β secretionNLRP3 inflammasome complexHypoxia-inducible factorThromboembolic eventsProinflammatory stateSystemic hypoxiaThrombotic eventsPreclinical findingsAltered hemostasisRisk factorsCardiovascular conditionsCommon causeInflammasome activationThrombosisHealthy individualsPyrin domainHIF-1α
2016
Endothelin-1 Gene Polymorphism and Its Level Predict the Risk of Venous Thromboembolism in Male Indian Population
Kumari B, Prabhakar A, Sahu A, Chatterjee T, Tyagi T, Gupta N, Nair V, Ashraf M. Endothelin-1 Gene Polymorphism and Its Level Predict the Risk of Venous Thromboembolism in Male Indian Population. Clinical And Applied Thrombosis/Hemostasis 2016, 23: 429-437. PMID: 27481876, DOI: 10.1177/1076029616661416.Peer-Reviewed Original ResearchConceptsVenous thromboembolismGene polymorphismsEndothelin-1Plasma levelsHealthy controlsG polymorphismOccurrence of VTEEnzyme (ACE) I/DEndothelial nitric oxide synthaseIndian populationEndothelin-1 gene polymorphismsLogistic regression model analysisEnzyme-linked immunoassay kitNitric oxide synthaseRegression model analysisEndothelial functionClinical progressionVascular functionOxide synthaseG alleleSignificant associationIndividual susceptibilityImmunoassay kitPatientsThromboembolism
2015
Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action
Rashid Q, Abid M, Gupta N, Tyagi T, Ashraf M, Jairajpuri M. Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action. BioMed Research International 2015, 2015: 630482. PMID: 25866798, PMCID: PMC4381846, DOI: 10.1155/2015/630482.Peer-Reviewed Original ResearchConceptsFavorable safety profileNovel anticoagulant agentsForm of heparinAnticoagulant administrationSafety profileAntithrombotic agentsAnticoagulant agentsAnticoagulant factorsHemostatic balanceAntithrombotic potentialLow doseAntiplatelet mechanismFibrinolytic systemPlatelet aggregationThrombotic ratsFirst lineHeparinCoagulation timeRatsBlood plasmaNovel compoundsThromboembolismComplicationsAnticoagulantsTherapy